NOCIVA Splice Variant Biomarker for AML Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for acute myeloid leukemia (AML) lack sensitivity for stratifying patients according to prognosis, leading to inadequate treatment strategies, as existing markers do not effectively differentiate between favorable and poor prognosis patients, and there is a need for new molecular markers for monitoring minimal residual disease.
Innovation Solution
Identification of a novel splice variant of CIP2A, named NOCIVA, which serves as a biomarker for cancer diagnosis and prognosis, including AML, through specific antibodies, probes, and primers that target NOCIVA, allowing for its detection and quantification in patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods and existing markers are used for AML patient stratification, then the diagnostic process is simple and familiar, but the sensitivity and accuracy for differentiating prognosis groups is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by introducing a novel splice variant marker (NOCIVA) that specifically targets a distinct molecular subgroup of AML patients. This segmentation enables differentiation between favorable and poor prognosis groups that were previously indistinguishable using conventional markers, thereby improving measurement precision without requiring complete overhaul of existing diagnostic infrastructure
Solution Approach 2:
The patent changes the molecular parameter being measured by shifting from conventional markers to the novel NOCIVA splice variant. This parameter change reveals previously hidden prognostic information, allowing accurate stratification of patients into distinct prognosis groups. The change is implemented through targeted molecular testing that can be integrated into existing diagnostic workflows
2Reliability
If new molecular markers like NOCIVA are introduced for AML prognosis, then the accuracy of patient stratification improves, but the complexity of diagnostic procedures increases
Solution Approach 1:
The patent performs preliminary action by identifying and validating the NOCIVA splice variant as a reliable prognostic marker before clinical implementation. Extensive validation has been completed to establish its reliability in predicting poor prognosis, ensuring that when the test is deployed, it immediately provides high-confidence results without requiring complex interpretation or additional validation steps in clinical settings
Solution Approach 2:
The patent introduces NOCIVA as an intermediary molecular marker that bridges the gap between conventional diagnostic markers and the actual prognostic outcome. This intermediary provides specific molecular information about PP2A pathway dysfunction that directly correlates with poor prognosis, serving as a reliable mediator that translates molecular biology into clinically actionable prognostic information
3Adaptability or versatility
If conventional PCR tests for fusion genes and mutations are used, then the testing procedure is standardized and widely available, but only half of AML patients have relevant molecular genetic tests available
Solution Approach 1:
The patent achieves universality by developing a diagnostic approach based on NOCIVA splice variant detection that is applicable across all AML patient populations, regardless of their specific fusion gene or mutation status. Unlike conventional tests that target specific genetic abnormalities present in only subsets of patients, the NOCIVA marker provides relevant prognostic information for all AML cases, making the diagnostic system universally applicable
Solution Approach 2:
The patent employs partial action by focusing on detecting the specific NOCIVA splice variant rather than attempting to identify all possible molecular abnormalities in AML. This targeted approach provides sufficient prognostic information for risk stratification without requiring comprehensive testing of all potential molecular alterations, thereby increasing marker applicability while maintaining diagnostic efficiency
Data Source
AI summary
The present invention relates to a novel cancer-associated biomarker and different applications and uses thereof. More specifically, the invention relates to a novel splice variant of CIP2A denoted as NOCIVA, as well as binding bodies such as probes, amplification primers, and antibodies specific for the same. Also provided are various methods for detecting and prognosing cancer on the basis of said splice variant, and a kit for use in said methods.